The Task Force on Catastrophic Antiphospholipid Syndrome (CAPS) met again on occasion of the 16th International Congress on Antiphospholipid Antibodies (aPL) that was held in Manchester, England, in September 2019. Its aims were to assess the up-to-date knowledge on pathogenesis, clinical and laboratory features, diagnosis and classification, precipitating factors, and treatment of CAPS. This article summarizes the main aspects that were presented during the Task Force meeting at that Congress.
CerveraRRodríguez-PintóIEspinosaG.The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun2018;
92: 1–11.
2.
BermanHRodríguez-PintóICerveraR, et al.
Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS registry”. Autoimmun Rev2014;
13: 157–162.
3.
Rodríguez-PintóIMoitinhoMSantacreuI, et al.
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the international CAPS registry. Autoimmun Rev2016;
15: 1120–1124.
4.
Rodríguez-PintóIEspinosaGErkanD, et al.
The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford)2018;
57: 1264–1270.
5.
BermanHRodríguez-PintóICerveraR, et al.
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev2013;
12: 1085–1090.
6.
UnluOErkanD.Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease. Annu Rev Med2017;
68: 287–296.
7.
LegaultKLSchunemannHJHillisC, et al.
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost2018;
16: 1656–1664.
8.
GuyattGHOxmanADVistGE, et al.; GRADE Working Group.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;
336: 924–926.
9.
SchünemannHJWierciochWEtxeandiaI, et al.
Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ2014;
186: 123–142.
Alonso-CoelloPOxmanADMobergJ, et al.
GRADE working group. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ2016;
353: i2089.
12.
Alonso-CoelloPSchünemannHJMobergJ, et al.
GRADE working group. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ2016;
353: i2016.
13.
LegaultKLHillisCYeungC, et al.
THU0561 clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome. Ann Rheum Dis2017;
76: 418–419.
AshersonRACerveraRde GrootP, et al.
Catastrophic antiphospholipid syndrome (CAPS): international consensus statement on classification criteria and treatment guidelines. Lupus2003;
12: 530–534.
17.
GeorgeJNNesterCM.Syndromes of thrombotic microangiopathy. N Engl J Med2014;
371: 1847–1848.
18.
BayraktarUDErkanDBucciarelliSEspinosaGCerveraRAshersonR.Catastrophic antiphospholipid syndrome (CAPS): comparison between CAPS patients with and without thrombocytopenia. Clin Exp Rheumatol2007;
25: 14.
19.
RedechaPTilleyRTencatiM, et al.
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood2007;
110: 2423–2431.
20.
ChaturvediSBrodskyRAMcCraeKR.Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol2019;
10: 449.
21.
ErkanDSalmonJE.The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk J Haematol2016;
33: 1–7.
22.
KelloNKhouryLEMarderGFurieRZapantisEHorowitzDL.Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature. Semin Arthritis Rheum2019;
49: 74–83.
KronbichlerAFrankRKirschfinkM, et al.
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore)2014;
93: e143.
25.
ChaturvediSBraunsteinEMYuanX, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood2020; 135: 239–251.
26.
OrtelTLErkanDKitchensCS.How I treat catastrophic thrombotic syndromes. Blood2015;
126: 1285–1293.
27.
SevimEWillisRErkanD.Is there a role for immunosuppression in antiphospholipid syndrome?Hematology Am Soc Hematol Educ Program2019;
2019: 426–432.
